Industry Insights
Sep 01, 2026 · 1 min read · 8,768 views
Lack of biosimilar development could cost billions in lost savings, report warns
A
Aiden Brooks
Editorial · Sep 01, 2026
Reports indicate that the findings underscore one of the hard truths of the US drug market: Cheaper options can only reach patients if they're made
← Previous
Replimune melanoma drug snags coveted FDA approval after yearlong clash, two rejections
Next →
Scholar Rock gets FDA nod for spinal muscular atrophy drug
